• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sean Whooley

Data shows cost benefits with Pear Therapeutics digital therapeutic for opioid use disorder

June 14, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) today shared real-world data highlighting low costs with its reSET-O prescription digital therapeutic (PDT). Boston-based Pear Therapeutics’ reSET-O represents the only FDA-authorized PDT for the treatment of opioid use disorder (OUD). According to a news release, results from a 12-month, real-world data study of reSET-O demonstrated reduced healthcare resource utilization and associated […]

Filed Under: Big Data, Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Neurological, Patient Monitoring Tagged With: Pear Therapeutics

Early study supports experimental hydrogel injection for chronic low back pain

June 13, 2022 By Sean Whooley

ReGelTec Hydrafil System Hydrogel

A study demonstrated that an experimental hydrogel formulation was safe and effective in substantially relieving chronic low back pain. Research presented at the Society of Interventional Radiology Annual Scientific Meeting in Boston supported the hydrogel, which was injected into spinal discs in an effort to relieve chronic low back pain caused by degenerative disc disease […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Hydrogels, Orthopedics, Pain Management Tagged With: hydrogels, ReGelTec

Dexcom quadruples number of shares

June 13, 2022 By Sean Whooley

Dexcom updated logo

Dexcom (Nasdaq:DXCM) recently filed a restated certificate of incorporation to effect a four-for-one forward stock split. Shares of DXCM were down 0.9% at $293.85 per share at market close on Friday, June 10. Following the stock split, shares moved down 75.33% to $72.50 before the market opened this morning. At market open, shares were down […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Wall Street Beat Tagged With: Dexcom

Data supports Beta Bionics’ iLet bionic pancreas

June 9, 2022 By Sean Whooley

Beta Bionics - updated logo

Beta Bionics announced today that a trial of its iLet bionic pancreas met key endpoints, including reduced HbA1c. Dr. Roy W. Beck and clinical investigators presented the results of the multi-center, randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. Read: The biggest stories […]

Filed Under: Auto-injectors, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Beta Bionics

DarioHealth closes $50M loan facility with OrbiMed

June 9, 2022 By Sean Whooley

DarioHealth

DarioHealth (Nasdaq:DRIO) announced today that it closed a senior secured term loan facility worth up to $50 million. OrbiMed, a leading healthcare investor, will provide non-dilutive capital to fund the continued development of New York-based DarioHealth’s digital health platform for managing chronic diseases, including diabetes. According to a news release, the five-year, $50 million facility includes […]

Filed Under: Business/Financial News, Diabetes, Funding Roundup, Technology Tagged With: dariohealth, OrbiMed

Pear Therapeutics reports positive real-world data for chronic insomnia treatment

June 8, 2022 By Sean Whooley

Pear Therapeutics

Pear Therapeutics (Nasdaq:PEAR) today announced real-world data from a trial of its Somryst prescription digital therapeutic (PDT). Data showed that Somryst, the only FDA-authorized PDT for treating chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity both immediately following treatment and at six-months follow-up. Boston-based Pear Therapeutics presented results at the […]

Filed Under: Clinical Trials, Neurological, Technology Tagged With: Pear Therapeutics

First patient enrolled in MedAlliance’s drug-eluting balloon trial

June 8, 2022 By Sean Whooley

MedAlliance SELUTION SLR

MedAlliance announced today that the first patient was enrolled in a trial of its Selution SLR sirolimus-eluting balloon. Last month, the company received FDA investigational device exemption (IDE) for the Selution SLR drug-eluting balloon, which it designed to provide a controlled sustained drug release, similar to a drug-eluting stent. The FDA IDE BTK (below-the-knee) Selution4BTK […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Food & Drug Administration (FDA), Vascular Tagged With: MedAlliance

The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions

June 8, 2022 By Sean Whooley

American Diabetes Association Abbott FreeStyle Libre 3 Dexcom G7 Insulet Omnipod 5 Medtronic MiniMed 780G

For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space. Major players like Dexcom, Medtronic, Abbott, Insulet and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table. […]

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, American Diabetes Association, Bigfoot Biomedical, dariohealth, Dexcom, Insulet, Medtronic, One Drop, Tandem Diabetes Care, Virta Health

Digital therapeutics developer Better Therapeutics names new CEO

June 7, 2022 By Sean Whooley

Better Therapeutics

Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Frank Karbe as its new president and CEO. San Francisco-based Better Therapeutics develops prescription digital therapeutics (PDTs) based on nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases. Karbe will join the company as president and CEO and will serve as a member […]

Filed Under: Business/Financial News, Diabetes, Neurological, Patient Monitoring, Personnel, Technology Tagged With: Better Therapeutics, Personnel, Personnel Moves

Sernova touts data on implantable cell pouch for treating insulin-dependent diabetes

June 7, 2022 By Sean Whooley

Sernova Cell Pouch System

Sernova announced clinical data supporting the potential of its Cell Pouch system as a “functional cure” for insulin-dependent diabetes. London, Ontario-based Sernova designed its proprietary Cell Pouch system as an implantable and scalable medical device that forms a natural environment in the body for long-term survival and function of therapeutic cells that release necessary proteins […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations Tagged With: Sernova Inc

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Interim pages omitted …
  • Go to page 76
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS